title: Diffuse Reactive Angioendotheliomatosis Secondary to the Administration of Trabectedin and Pegfilgrastim.
abstract: Diffuse dermal angiomatosis is a rare benign condition considered a variant of reactive angioendotheliomatosis, usually related to vascular disease such as arteriovenous fistula or severe peripheral vascular disease. The most frequent clinical manifestations range from a solitary erythematous patch to an indurated plaque that may ulcerate. A clinical case of a 60-year-old woman who developed generalized livedoid lesions 2 days after the administration of intravenous trabectedin and subcutaneous pegfilgrastim for a recidivant myxoid liposarcoma has been reported. A biopsy of the skin lesions showed a pronounced proliferation of vessels in the upper dermis that was diagnosed as diffuse dermal angiomatosis.
authors.affiliation: Departments of *Dermatology, and †Pathology, La Paz University Hospital, Madrid, Spain.
authors.forename: Ander
authors.initials: A
authors.lastname: Mayor-Ibarguren
authors.forename: Cristina
authors.initials: C
authors.lastname: Gómez-Fernández
authors.forename: María J
authors.initials: MJ
authors.lastname: Beato-Merino
authors.forename: Jéssica
authors.initials: J
authors.lastname: González-Ramos
authors.forename: Ana I
authors.initials: AI
authors.lastname: Rodríguez-Bandera
authors.forename: Pedro
authors.initials: P
authors.lastname: Herranz-Pinto
mesh_terms: D000798:Angiomatosis / Q000139:chemically induced* / Q000473:pathology; D018952:Antigens, CD34 / Q000032:analysis; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects; D049109:Cell Proliferation; D004149:Dioxoles / Q000009:adverse effects; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D042783:Endothelial Cells / Q000737:chemistry / Q000187:drug effects* / Q000473:pathology; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects; D006801:Humans; D008875:Middle Aged; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000032:analysis; D011092:Polyethylene Glycols; D011994:Recombinant Proteins / Q000009:adverse effects; D017445:Skin Diseases, Vascular / Q000139:chemically induced* / Q000473:pathology; D044005:Tetrahydroisoquinolines / Q000009:adverse effects; D000077606:Trabectedin
chemical_list: D018952:Antigens, CD34; D018906:Antineoplastic Agents, Alkylating; D004149:Dioxoles; D019408:Platelet Endothelial Cell Adhesion Molecule-1; D011994:Recombinant Proteins; D044005:Tetrahydroisoquinolines; D016179:Granulocyte Colony-Stimulating Factor; C455861:pegfilgrastim; D011092:Polyethylene Glycols; D000077606:Trabectedin; D000069585:Filgrastim